Consumers in Switzerland still pay more for pharmaceuticals than in other European countries, but the gap continues to narrow.
This content was published on
1 minute
swissinfo.ch and agencies
However, generic drugs are nearly twice as expensive as the combined average of France, Germany, Austria, Denmark, the Netherlands and Britain, according to a survey published by the health sector on Tuesday.
The 200 patented drugs generating the biggest turnover are around six per cent more expensive in Switzerland, a drop of three per cent over 2009.
The prices of several hundreds of drugs went down in Switzerland in March after the government ordered some price controls. These controls will take place once every three years, from now on.
The industry expects the price difference for generics to be reduced further next year following an announcement by the interior ministry to reduce prices.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Health bosses move to boost cancer jabs
This content was published on
Switzerland rolled out a programme in 2008 to vaccinate girls and young women aged 11 to 19 against the human papilloma virus, or HPV, which causes around 2,000 Swiss women to develop the early stages of cervical cancer every year. But at the start of 2010, just 36 per cent of the age group had…
This content was published on
They hope that mechanism by which it works – which has never been seen before – could eventually be applied to other such bugs. Big pharmaceutical companies have already expressed an interest. The joint research team from Zurich University and Swiss biotech company Polyphor has described the new drug class as a rare and significant…
This content was published on
Having trailed behind Roche over the last few years, Novartis appeared to have turned a corner with a record-breaking performance in 2009. Roche is tipped to amply recoup the acquisition costs that dented its 2009 profits. Both Basel-based firms are standing on solid foundations and are poised to reap strong benefits in the next two…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.